Clinical Trials Directory

Trials / Completed

CompletedNCT03800576

Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

The Influence of Genetic and Clinical Factors on Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

Status
Completed
Phase
Study type
Observational
Enrollment
113 (actual)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Genetic polymorphism and numerous clinical factors could influence tacrolimus pharmacokinetics, which led to large inter-and intra-individual variability.Since its narrow therapeutic range,predicting therapeutic outcome and individualized dosage remains to be a challenge. The study's objective is to identify the genetic and clinical factors that can influence clinical outcome in liver transplant.

Detailed description

A great number of studies had found significant correlation between tacrolimus pharmacokinetics and gene polymorphism. However, previous studies on the correlation between genetic factors and clinical outcome were controversial. Furthermore, most studies focused on single genetic polymorphism and clinical outcome, and very limited studies took multiple genetic factors and clinical factors into account. This is a retrospective study. Eligible patients were those who had signed informed consent for genetic study in previous research projects ( IRB approval number:201512005RINC and 201612023RIND ). The present study will collect laboratory data, concurrent medications, and therapeutic drug monitoring (TDM) data. Patient survival, graft survival, acute rejection and tacrolimus-associated adverse events will be assessed.

Conditions

Timeline

Start date
2019-06-06
Primary completion
2019-10-08
Completion
2020-09-22
First posted
2019-01-11
Last updated
2021-03-16

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03800576. Inclusion in this directory is not an endorsement.